



NETWORK Notification

Notice Date: October 1, 2025
To: Ohio Providers
From: CareSource
Subject: Audaire Health Provider Portal
Effective Date: November 1, 2025

Summary

Starting November 1, 2025, CareSource requires providers administering cell and gene therapies to enter clinical outcomes data into the [Audaire Health provider portal](#) for our Ohio members. This initiative supports value-based tracking of treatment effectiveness, which aims to reduce administrative burden and assess clinical benefits of these therapies.

Beginning November 1, 2025, clinical outcomes for members approved for Chimeric Antigen Receptor Therapy (CAR-T) must be reported in the Audaire Health portal.

Currently available CAR-T cell therapies:

HCPCS CODE	BRAND NAME	GENERIC NAME
Q2055	ABECMA	Idecabtagene vicleucel
Q2058	AUCATZYL	Obecabtagene autoleucel
Q2054	BREYANZI	Lisocabtagene autoleucel
Q2056	CARVYKTI	Ciltacabtagene autoleucel
Q2042	KYMRIAH	Tisagenlecleucel
Q2053	TECARTUS	Brexucabtagene autoleucel
Q2041	YESCARTA	Axicabtagene ciloleucel

Note: Clinical outcomes for CAR-T therapies FDA-approved after November 1, 2025, will also be tracked in the Audaire Health provider portal.

Key Changes and Provider Responsibilities

- **Attestation Required:** Prior authorization approvals for any CAR-T therapy will require provider attestation to submit outcomes in Audaire
- **Data Entry:** Clinical outcomes data must be submitted to Audaire Health using one of the following methods:
 - Online portal submission at: www.audaire.com/portal
 - By phone or fax with an Audaire representative
- **Timing:** Outcomes tracking – 3 months, 6 months, 12 months and 24 months – starting from the end date of the authorization period
- **Training:** Providers will receive onboarding support and access to Audaire training materials
- **Time frame:** Applies to authorizations approved on or after November 1, 2025

Additional Notes

Outcomes tracking may also apply to other cell and gene therapies. Monitor for future updates via CareSource Provider Network notifications for the addition of other therapies.

Additional information is available in the **CareSource Audaire Health Cell and Gene Therapy (CGT) Outcomes Tracking Program – Frequently Asked Questions for Providers**.

Questions?

For questions regarding the Audaire Health Implementation, please email CareSource Ohio Pharmacy at CareSourceOHRx@CareSource.com.

H8452_OH-MYC-P-4537609